Evolution of Care in Myeloproliferative Neoplasms: A Clinical Perspective
Pankit Vachhani, MD; Edward Pearson, MD, and Maureen Thyne, PA, discuss evidence-based approaches to myeloproliferative neoplasms, highlighting Janus kinase inhibitor selection strategies for myelofibrosis based on patient-specific factors such as cytopenia profiles and splenomegaly severity while addressing polycythemia vera management through strict hematocrit control, molecular monitoring, and emerging therapies including ruxolitinib, interferons, and hepcidin mimetics that offer disease modification beyond symptom control.
Panelists discuss how advancements in understanding myeloproliferative neoplasms are shaping treatment approaches through case studies of intermediate-risk myelofibrosis and advanced polycythemia vera, with emphasis on Janus kinase (JAK) inhibitor selection based on genetic profiles and patient-specific factors.
Watch
Panelists discuss how treatment selection among Janus kinase (JAK) inhibitors for myelofibrosis involves considering specific patient characteristics such as cytopenia profiles, mutation status, risk stratification using MIPS criteria, and balancing potential transplant candidacy with careful timing of JAK inhibitor therapy.
Watch
Panelists discuss how treatment goals for intermediate-risk myelofibrosis patients focus on achieving meaningful clinical outcomes including relieving symptoms, preventing worsening of anemia, maintaining transfusion independence, reducing symptomatic splenomegaly, and ultimately improving survival while considering patient-specific factors like age and transplant eligibility.
Watch
EP. 4: COMFORT Trials: Applying Evidence to Intermediate-Risk Myelofibrosis
April 23rd 2025Panelists discuss how clinical trial data from the COMFORT studies supports using Janus kinase (JAK) inhibitors such as ruxolitinib for myelofibrosis patients beyond the original high-risk study population, with experts noting they often treat intermediate-1-risk patients based on symptomatic burden and splenomegaly rather than risk stratification alone to achieve meaningful spleen volume reduction and symptom improvement.
Watch
